All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
MPL W515 mutations, CALR exon 9 mutations, and the most frequent mutation observed in MPN, JAK2 V617F, which results in ligand-independent proliferation, are all considered to be key driver mutations of MPN pathogenesis. The term ‘triple-negative’ refers to the absence of mutations in three key driver genes, JAK2, CALR, or MPL. However, patients with triple-negative MPN can carry mutations in other genes.
Save to your areas of interest